Find Clinical Trial

Assessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg on request (maximum 5 times a day) on the top of L-dopa and a dopamine agonist in advanced Parkinson Disease patients with motor fluctuations: a 4-week open label pilot study


← Back
Study Phase

Phase 3

Therapeutic Area

Neuropsychiatric Diseases

IndicationParkinson's disease
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

PIRIBEDIL,
S090049

Active Substance CodeS090049
Protocol CodeSC3-90049-001
EudraCT Code2005-002010-38




Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2020 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility